Cmd in aki and ckd
Reading Document
Medical Text Search
coronary microvascular dysfunction CMD in acute kidney injury AKI
Medical Text Search
coronary microvascular dysfunction CMD in chronic kidney disease CKD
GradeResponse
GradeResponse
The retrieval is sparse on CMD specifically. I'll synthesize a comprehensive answer from my clinical knowledge, supplemented by what was retrieved.
Coronary Microvascular Dysfunction (CMD) in AKI and CKD
Overview
Coronary Microvascular Dysfunction (CMD) refers to functional and/or structural abnormalities of the coronary microvasculature (vessels < 500 µm) that impair myocardial perfusion in the absence of obstructive epicardial coronary artery disease (CAD). Both AKI and CKD create a pro-inflammatory, uremic, hemodynamic milieu that profoundly accelerates CMD.
Pathophysiology of CMD in Kidney Disease
Shared Mechanisms (AKI + CKD)
| Mechanism | Effect on Coronary Microvasculature |
|---|---|
| Systemic inflammation (IL-6, TNF-α, CRP) | Endothelial activation, reduced NO bioavailability, capillary rarefaction |
| Oxidative stress | Peroxynitrite-mediated endothelial injury, impaired vasodilation |
| Sympathetic/RAAS activation | Vasoconstriction, microvascular remodeling |
| Uremic toxins (indoxyl sulfate, p-cresol sulfate) | Endothelial dysfunction, vascular smooth muscle hypertrophy |
| Anemia | Compensatory tachycardia, increased wall stress, microvascular shear stress |
| Fluid overload / hypertension | Increased LV mass, impaired subendocardial perfusion |
CMD in Acute Kidney Injury (AKI)
Specific Mechanisms
- Ischemia-reperfusion injury: AKI triggers systemic release of DAMPs (damage-associated molecular patterns), causing distant organ (including cardiac) microvascular endothelial injury — the cardiorenal syndrome type 3 axis.
- Cytokine storm: Acute elevation of IL-1β, TNF-α directly impairs coronary microvascular tone.
- Volume dysregulation: Rapid fluid shifts alter coronary perfusion pressure and capillary hydrostatic pressures.
- Hemodynamic instability (sepsis-related AKI): Distributive shock causes impaired coronary autoregulation.
Clinical Implications in AKI
- Troponin elevation in AKI is partly driven by CMD-mediated demand ischemia (Type 2 MI pattern)
- CMD contributes to reduced coronary flow reserve (CFR) acutely, potentially reversible if AKI resolves
- Patients with AKI after cardiac surgery (post-cardiotomy AKI) show bidirectional injury — CMD worsens renal perfusion, and AKI worsens CMD
Cardiorenal Syndrome (CRS) Link
| CRS Type | Directionality | CMD Role |
|---|---|---|
| Type 1 | Acute cardiac → AKI | Reduced CO → renal ischemia |
| Type 3 | AKI → Acute cardiac dysfunction | Inflammatory/uremic CMD |
CMD in Chronic Kidney Disease (CKD)
Specific Mechanisms
- Capillary rarefaction: CKD causes structural loss of myocardial microvessels, reducing microvascular density
- Accelerated arteriolosclerosis: Hyalinization of arterioles from hypertension + uremia reduces vasodilatory reserve
- Phosphate/FGF-23 excess: Elevated FGF-23 (present early in CKD) independently causes LV hypertrophy and CMD via endothelial dysfunction
- Calcium-phosphate deposition: Medial calcification of microvasculature
- Endothelial dysfunction: Reduced eNOS activity, asymmetric dimethylarginine (ADMA) accumulation inhibits NO synthesis
- Autonomic neuropathy (uremic): Impaired coronary vasomotor regulation
CMD Manifestations in CKD
- Reduced Coronary Flow Reserve (CFR < 2.0): Present in up to 50–70% of CKD/ESRD patients even without obstructive CAD
- Increased Index of Microcirculatory Resistance (IMR)
- Microvascular angina: Anginal symptoms with normal epicardial coronaries — common in CKD
- LV hypertrophy + diastolic dysfunction: CMD reduces subendocardial perfusion → fibrosis → diastolic dysfunction (CKD cardiomyopathy)
- Silent ischemia: High prevalence due to autonomic/sensory neuropathy masking symptoms
Hemodialysis Patients
- Intradialytic hypotension causes repeated myocardial stunning via CMD
- Arteriovenous fistula increases cardiac output demand, stressing already dysfunctional microvasculature
- Myocardial hibernation and regional wall motion abnormalities can occur without obstructive CAD
Diagnosis of CMD in Kidney Disease
Non-Invasive
| Test | Finding in CMD | Caveat in CKD |
|---|---|---|
| Stress Echo | Reduced CFR (TTDE Doppler on LAD), regional WMA | Suboptimal windows common |
| PET Myocardial Perfusion Imaging | Reduced absolute myocardial blood flow, CFR < 2.0 | Gold standard; adenosine may be needed |
| Cardiac MRI | Microvascular obstruction, subendocardial perfusion defects | Gadolinium contraindicated in eGFR < 30 (NSF risk) |
| CTCA + CT perfusion | Contrast load concern | Minimize contrast; pre-hydration critical |
Invasive (Cardiac Catheterization)
| Index | Threshold | Interpretation |
|---|---|---|
| CFR (Coronary Flow Reserve) | < 2.0 | CMD present |
| IMR (Index of Microcirculatory Resistance) | > 25 | Structural CMD |
| HMR (Hyperemic Microvascular Resistance) | > 2.5 | Functional CMD |
| RRR (Resistance Reserve Ratio) | < 3.5 | CMD |
Note: Contrast use in catheterization should be minimized in CKD — use iso-osmolar contrast (iodixanol), limit volume (contrast dose/eGFR ratio < 3.0–3.7), and ensure adequate pre-hydration with IV saline or sodium bicarbonate.
Management of CMD in AKI and CKD
General Principles
- Treat the underlying kidney disease — reversing AKI or slowing CKD progression reduces CMD burden
- Aggressive cardiovascular risk factor management: hypertension, dyslipidemia, anemia, hyperphosphatemia
Pharmacological Strategies
| Drug Class | Mechanism | Evidence |
|---|---|---|
| ACE inhibitors / ARBs | Reduce RAAS-driven microvascular remodeling; decrease ADMA | First-line in CKD with proteinuria; caution in bilateral RAS or AKI |
| SGLT2 inhibitors | Reduce inflammation, improve endothelial function, renoprotection | Benefit in CKD (DAPA-CKD, CREDENCE); emerging CMD data |
| Statins | Pleiotropic endothelial effects, reduce oxidative stress | Standard in CKD cardiovascular management |
| Ranolazine | Reduces late INa, improves subendocardial perfusion | Used in microvascular angina; renal dose adjustment needed |
| Nicorandil | K-ATP channel opener; microvascular vasodilation | Used in microvascular angina |
| CCBs (amlodipine) | Microvascular vasodilation | Useful for vasospastic component; safe in CKD |
| Beta-blockers | Reduce demand ischemia | Use with caution in dialysis patients (hemodynamic instability) |
| EPO / ESA | Correct anemia (Hb target 10–11.5 g/dL) | Reduces CMD-related demand ischemia; avoid supranormal Hb |
| Phosphate binders / calcitriol | Reduce FGF-23, vascular calcification | Indirect CMD benefit |
Revascularization
- PCI/CABG for obstructive CAD has limited benefit in advanced CKD (per ISCHEMIA-CKD trial — invasive strategy did not reduce death/MI vs. medical therapy alone at 2.2 years)
- CMD itself is not amenable to revascularization — medical and risk factor optimization is the cornerstone
- Renal transplantation may partially improve CMD by removing the uremic milieu
Key Takeaways
- CMD is highly prevalent in both AKI and CKD and is a major contributor to cardiovascular mortality in these populations
- In AKI, CMD is largely functional/inflammatory and may be reversible with kidney recovery
- In CKD, CMD is structural (capillary rarefaction, fibrosis, calcification) and progressive
- CFR < 2.0 on PET or invasive assessment is the diagnostic benchmark
- Management is medical-first: RAAS blockade, SGLT2i, statins, anemia/phosphate control, and targeted anti-anginal therapy
- ISCHEMIA-CKD trial data confirm revascularization does not improve outcomes over medical therapy in CKD with stable ischemia (Perioperative Cardiovascular Evaluation and Management, p. 68)
This is a shared conversation. Sign in to Orris to start your own chat.